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Cyclooxygenase-1-Coupled Prostaglandin Biosynthesis
Constitutes an Essential Prerequisite for Skin Repair
Heiko Kmpfer, Lutz Brutigam, Gerd Geisslinger, Josef Pfeilschifter, and Stefan Frank
Pharmazentrum Frankfurt Theodor-Stern-Kai 7, D-60590 Frankfurt/Main, Germany
This investigation demonstrated a functional coupling
between cyclooxygenase-1 (cox) and prostaglandin
E2/D2 biosynthesis in murine skin repair. Cyclooxygen-
ase-1 expression decreased transiently after excisional
wounding, and this was followed by a marked fall in
the rate of prostaglandin E2/D2 biosynthesis at the
wound site. Expression of cyclooxygenase-1, prosta-
glandin synthases, and prostaglandin E2/D2 production
were colocalized in new tissue at the margin of the
wound. Although cyclooxygenase-2 expression was
strongly induced in granulation tissue on injury, this
isoform did not contribute to high prostaglandin E2/D2
concentrations in wounds. Accordingly, wound tissue
from SC-560-treated mice (selective cyclooxygenase-1
inhibitor) and diclofenac-treated mice (nonselective
cyclooxygenase inhibitor), but not celecoxib-treated
mice (selective cyclooxygenase-2 inhibitor), and wound
tissue from cyclooxygenase-1-de¢cient animals exhib-
ited a severe loss of prostaglandin E2/D2 at the wound
site, and this change was associated with an impairment
in the normal wound morphology. Topically adminis-
tered prostaglandin E2 (dinoprostone) was able to re-
store normal wound repair to diclofenac-treated mice.
In contrast to the presence of an injury-induced cy-
clooxygenase-2, these data constitute strong evidence
that cyclooxygenase-1-coupled prostaglandin E2/D2
biosynthesis has a central role in skin repair. Key words:
non-steroidal anti-in£ammatory agents/dinoprostone/keratino-
cytes/knock-out mice/prostaglandin endoperoxidase synthase.
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N
onsteroidal anti-in£ammatory drugs (NSAID) are
among the most widely used therapeutic agents. It
has long been known that these drugs exert both
their wanted and unwanted e¡ects by inhibition
of prostaglandin (PG) synthesis (Vane et al, 1994).
Accordingly, currently available NSAID are now well established
to inhibit the PG synthesizing enzymes cyclooxygenase (COX)-1
and COX-2 (Meade et al, 1993). In general, COX-1 is assumed to
represent the constitutively expressed isoform that is present in
most cells and nearly all tissues (Cro¡ord, 1997). In contrast, the
COX-2 isoenzyme is not abundantly expressed but can be in-
duced, especially in immune cells (Masferrer et al, 1990; Lee et al,
1992; Smith and DeWitt, 1996). COX activity contributes to the
maintenance of body homeostasis, where the inducible COX-2
in particular appears to play a key part in a series of pathologic
conditions such as in£ammation, pain, Alzheimer’s disease, and
cancer (Dubois et al, 1998).
The occurrence of gastrointestinal side-e¡ects are major limita-
tions in NSAID therapy, and because of this COX expression and
activity have been extensively studied in models of gastric ulcera-
tion and healing (Stenson, 1997). Remarkably, gastric damage was
restricted to enzymatic inhibition of both COX isoenzymes
(Wallace et al, 2000). As in£ammation is central to the tissue re-
pair processes, a relationship between wound healing and COX-
mediated PG synthesis might be expected. Accordingly, COX-2
has been shown to promote ulcer healing (Mizuno et al, 1997;
Wallace et al, 1998). The role of COX isoenzymes in in£amma-
tion, however, could di¡er markedly. The constitutive COX-1 is
able to trigger in£ammatory responses whereas the inducible
COX-2 contributes to both the onset and decline of the in£am-
matory processes (Smith and Langenbach, 2001); however, func-
tional coupling of arachidonic acid (AA) availability, the activity
of COX isoforms, and subsequent PG biosynthesis appears to be
under subtle regulatory control. Immediate PG synthesis initiated
by COX-1 is favored by high amounts of AA. On the other
hand, it has been suggested that involvement of COX-2 rather
than COX-1 in delayed PG responses is because COX-2 is able
to metabolize low concentrations of AA (Murakami et al, 1999).
Thus, there is evidence that the COX isoenzymes are function-
ally associated with distinct components of the PG synthase ma-
chinery within the cell. In recent studies, COX-1 was shown to
be associated with cytosolic PGE2 synthase (cPGES) in immedi-
ate PGE2 synthesis (Tanioka et al, 2000), whereas the membrane-
associated PGE2 synthase (mPGES) is functionally coupled to
COX-2 in delayed responses (Murakami et al, 2000).
Although a recent study implicated a role for PG in skin morph-
ology and homeostasis (Neufang et al, 2001), the regulation of
COX isoenzyme expression and the availability and functional
role of PG after skin injury remains unknown.We therefore ex-
amined the regulation and potential function of COX iso-
enzymes and the PGE2/D2 biosynthetic machinery in skin repair.
Comparable with gastric ulcer healing, cutaneous wound healing
involves a series of well co-ordinated tissue changes such as
re-epithelialization, granulation tissue formation, and angiogen-
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esis, which together ensure an e⁄cient closure of the wound
(Martin, 1997; Singer and Clark, 1999). It is most important that
these tissue changes be closely regulated by the in£ammation pro-
cess and the in£ammation process itself be tightly controlled with
regard to initiation, maintenance, and resolution phases (Martin,
1997; Singer and Clark, 1999;Wetzler et al, 2000). Accordingly, the
participation of COX enzymes with the subsequent release of PG
might also be involved in the control of in£ammation in wounds
and skin repair. Here we report evidence for tight coupling of
COX-1 expression to PGE2/D2 levels in the region of wounds.
Moreover, COX-1 is shown to be colocalized with mPGE and
hematopoietic PGD synthase (hPGDS) expression at the
wound margins, where highest PGE2/D2 concentrations were
determined. Impairment of skin repair was demonstrated in
COX-1-dependent loss of PGE2/D2 production in inhibitor-
treated as well as in COX-1-de¢cient mice. Thus, this study pro-
vides evidence that COX-1 coupled PGE2/D2 biosynthesis plays
a crucial part in the regulation of the cutaneous wound healing
process.
MATERIALS AND METHODS
Animals Female BALB/C, or C57BLKS mice were obtained from
Charles River (Sulzfeld, Germany). Female B6; 129P2-Ptgs-1tm1 mice
(Langenbach et al, 1995) were purchased fromTaconic (Germantown, NY).
Treatment of mice Diclofenac (Sigma, Deisenhofen, Germany), SC-
560 (Witega, Berlin, Germany) or celecoxib (Celebrexs, Pharmacia AG,
Erlangen, Germany) were administered orally twice daily by gastrogavage
(2.5 mg per kg per 12 h). For systemic treatment, BALB/C mice were
injected intraperitoneally (i.p.) with 7.5 mg diclofenac per kg (Sigma) in
0.5 ml phosphate-bu¡ered saline (PBS) twice daily during healing. For
PGE2 treatment, BALB/C mice were treated topically twice daily with 8
mg per wound of dinoprostone (Minprostins, Pharmacia) in triacetine/
SiO2. Triacetine/SiO2 alone was used as a control.
Wounding of mice Full-thickness excisional wounding of mice was
performed as described previously (Frank et al, 1999; Stallmeyer et al,
1999). For each experimental time point, tissue from four wounds each
from four animals (n¼16 wounds, RNA analysis) and from two wounds
each from four animals (n¼ 8 wounds, protein analysis) were combined
and used for RNA and protein preparation. Nonwounded back skin from
four animals served as a control. All animal experiments were carried out
according to the guidelines and with the permission from the local
government of Hessen (Germany).
RNA isolation and RNase protection analysis RNA isolation and
RNase protection assays were carried out as described previously
(Chomczynski and Sacchi, 1987; Frank et al, 1999). The murine cDNA
probes were cloned using reverse transcription^polymerase chain reaction.
The probes corresponded to nucleotides (nt) 1682^1946 (for COX-1,
accession no. M34141), nt 796^1063 (for COX-2, accession no. M64291), nt
223^475 (for mPGES, accession no. AB041997), nt 792^947 (for cPGES,
accession no. AK007198), nt 286^551 [for lipocalin-type PGD synthase
(lPGDS), accession no. AB006361], nt 416^643 (for hPGDS, accession no.
D82072), nt 139^585 [for vascular endothelial growth factor (VEGF),
accession no. S38083], nt 816^1481 (for lipocalin, accession no. X81627),
nt 425 (exon1)^170 (exon 2) (for lysozyme M, accession no. M21047), nt
481^739 (for interleukin-1b, accession no. NM008361), nt 541^814 [for
tumor necrosis factor (TNF)-a, accession no. NM013693] or nt 163^317
(for GAPDH, accession no. NM002046) of the published sequences.
Preparation of protein lysates and western blot analysis Wound and
cell culture lysates were prepared as described previously (Kmpfer et al,
1999; Stallmeyer et al, 1999). Fifty micrograms of total protein from skin
or cellular lysates was separated using sodium dodecyl sulfate^gel
electrophoresis. COX-1, COX-2, and CD31 protein was detected using
polyclonal antibodies (anti-COX-1 sc-7950, anti-COX-2 sc-1746, and anti-
CD31 sc-1506 were from Santa Cruz, Heidelberg, Germany).
Immunohistochemistry Complete wounds were isolated from the
back, bisected, and frozen in tissue freezing medium. Six micrometer
frozen sections were subsequently analyzed using immunohistochemistry
as described (Stallmeyer et al, 1999). Polyclonal anti-sera against murine
COX-1, COX-2, and CD31 (Santa Cruz), Ki67 (Gerdes et al, 1984)
(Dianova, Hamburg, Germany), monoclonal anti-sera against murine
F4/80 antigen (Serotec, Eching, Germany), and murine Gr-1 (Ly-6G)
(Pharmingen, Hamburg, Germany) were used for immunodetection.
Enzyme-linked immunosorbent assay Total protein [50 mg diluted in
lysis bu¡er (Kmpfer et al, 1999) to a ¢nal volume of 50 ml] from skin
lysates was subsequently analyzed for the presence of immunoreactive
VEGF by enzyme-linked immunosorbent assay using the Quantikine
murine VEGF kit (R&D Systems,Wiesbaden, Germany).
Cell culture Quiescent murine 3T3 ¢broblasts were stimulated with
20% serum, or a combination of cytokines (2 nM interleukin-1b, 2 nM
TNF-a, 100 U per ml interferon-g). Murine RAW264.7 macrophages
were stimulated with 10 mg per ml lipopolysaccharide/100 U per ml
interferon-g. Lipopolysaccharide was purchased from Sigma, serum was
from Life Technologies (Karlsruhe, Germany), and cytokines were from
Roche (Mannheim, Germany).
Liquid chromatography tandem mass spectrometry (LC/MS/
MS) The LC unit consisted of a Jasco DG 1580^53 degasser, a Jasco LG-
1580-02 ternary gradient unit, a Jasco PU-1585 pump, and a Jasco AS 1550
autosampler (Gross-Umstadt, Germany). Detection was performed using a
PE Sciex API 3000 triple quadrupol mass spectrometer (Applied
Biosystems, Langen, Germany) equipped with a turbo ion spray interface.
Nitrogen (high purity) was supplied by a Whatman nitrogen generator
(Parker Hanni¢n GmBH, Kaarst, Germany).
Determination of diclofenac, celecoxib, and SC-560 Blood plasma
samples were obtained from treated animals 3 h following the last drug
administration for determination of diclofenac, celecoxib, and SC-560
plasma levels.
Diclofenac Two hundred milliliters of plasma and 400 ml 0.83 M
phosphoric acid in 10% sodium chloride solution were mixed and
extracted with 4 ml methylene chloride. After centrifugation the organic
layer was evaporated and the residue reconstituted with 200 ml mobile
phase. Ni£uminic acid was used as internal standard. The column used
was a Nucleosil C8 HD (Macherey-Nagel, Dueren, Germany). The
ultraviolet detector was set at a wavelength of 282 nm. The electronic data
were processed using Jasco Borwin software (Godbillon et al, 1985).
Celecoxib Plasma samples were extracted using acetonitrile/water/
ammonium hydroxide (85 : 14.9 : 0.1 v/v/v). The column used was a
Nucleosil C18 (Macherey-Nagel). Celecoxib was detected by LC/MS/MS.
The mass transitions used were m/z 380-316 and m/z 366-302 for
celecoxib and the internal standard (4-[5-phenyl-3-(tri£uoromethyl)-1H-
pyrazol-1-yl]benzenesulfonamide), respectively. The analytical data were
processed using Analyst software (version 1.1) (Brutigam et al, 2001).
SC-560 Plasma samples were extracted by solid-phase extraction,
and SC-560 was subsequently analyzed by high performance liquid
chromatography (Jasco) as described previously (Rose et al, 2000; Gr˛sch
et al, 2001).
Determination of PGE2 and PGD2 by LC/MS/MS Mice were
wounded as described above. After killing the mice, the wounds were
isolated from the backs of the animals and snap frozen in liquid nitrogen.
Frozen wound tissue was homogenized in PBS for 30 s, lysates cleared by
centrifugation (2000 g for 5 min) and 100 ml used to determine protein
concentrations (Bradford).Two milliliters of the supernatants were used for
the extraction of PG with 5 ml ethyl acetate and 20 ml formic acid for 15
min. The organic phase was separated by centrifugation (4000 g for 15
min) and the solvent evaporated. The pellet remaining was dissolved in
200 ml acetonitrile/water (80 : 20 v/v). Chromatographic separation of
extracted samples was performed in isocratic mode with a Nucleosil C18
column. The mass transitions used were m/z 351.2-315.1, 351.2-271.1,
and 351.2-189.1. The analytical data were processed using Analyst
software (version 1.1) (Brutigam et al, 2001). As PGE2 and PGD2 are
stereoisomers and thus resulted in the same fragments, it was not possible
to resolve both PG by MS/MS. Levels of PGE2 and PGD2 in the wound
are based on total wound protein.
Statistical analysis Data were shown as mean7SD. Data analysis was
carried out using the unpaired Student’s t test with raw data. Statistical
comparison between more than two groups was carried out by analysis of
variance (ANOVA, Bonferroni t test).
RESULTS
PGE2/D2 biosynthesis in normal and wounded skin As the
tightly controlled in£ammation process in wounds is associated
with skin regeneration (Martin, 1997; Singer and Clark, 1999;
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Wetzler et al, 2000), we ¢rst investigated expression patterns of
COX isoenzymes and various PG synthases in normal skin and
in skin after injury. Nonwounded skin was characterized by
constitutively expressed COX-1, whereas COX-2 expression was
absent (Fig 1a^c). After wounding, COX-1 and COX-2
expression appeared to be regulated biphasically and in an
opposite manner. COX-1 protein expression rapidly declined
shortly after wounding (Fig 1a), but COX-2 protein was
Figure1. PGE2/D2 biosynthetic pathways at the wound site. Regulation of COX-1 (a) and COX-2 (b,c) mRNA (upper panels) and protein (lower
panels) expression as assessed using the RNase protection assay or immunoblot. The time after injury is indicated for each lane. (d) Immunohistochemical
localization of COX-1 (upper panel) and COX-2 protein (lower panels) at the wound site on day 5 after injury. d, dermis; e, epidermis; f, ¢broblast, mf,
macrophages; bv, blood vessel; he, hyperproliferative epithelium. (e) RNase protection assay showing expression of various PGE2/D2 synthase isoforms
during skin repair.
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markedly induced at this stage (Fig 1b,c). Next, we directed our
attention to immunolocalize both COX isoforms in normal skin
and at the wound site (Fig 1d). COX-1was localized at epithelial
sites in nonwounded skin (Fig 1d, upper left panel) and at the
margins of the wound (5 d after injury) (Fig 1d, upper right
panel). Moreover, we detected COX-1 protein in ¢broblast-
shaped cells spotted within the granulation tissue (Fig 1d, small
panel). COX-2 protein was observed in neutrophils early after
wounding (data not shown), and was strongly expressed in
macrophages and blood vessels located in the granulation tissue
(5 d wound). Moreover, COX-2 was expressed in keratinocytes
of the developing wound margin epithelia. Note the perinuclear
staining of COX-2 protein in a number of keratinocytes (Fig 1d,
middle and lower panel).
Recent in vitro studies have provided strong evidence for a
functional coupling between COX isoenzymes and various PG
synthases (Murakami et al, 2000; Tanioka et al, 2000). We
addressed this point, and observed an induction of the mPGES
and the hPGDS after skin injury (Fig 1e), but the expression of
cPGES and the lPGDS was clearly attenuated during the ¢rst 7 d
of repair. Next, we determined wound PGE2/D2 levels as an
index of the overall wound COX/PG synthase enzyme activity.
In order to do this, we established a LC/MS/MS method for the
speci¢c determination of PGE2/D2 levels in the wound.
In line with our observation that COX-1 is expressed
constitutively (Fig 1a), nonwounded skin was characterized by
constitutively present PGE2/D2 (Fig 2). Although COX-2 and
mPGES/hPGDS were induced in injured skin (Fig 1b,c,e),
PGE2/D2 levels were reduced dramatically by 75% when
compared with those in normal skin (Fig 2). As skin repair
proceeds, PGE2/D2 concentrations returned to initial levels.
It is of interest that skin and also wound PGE2/D2 biosynthesis
was closely correlated with the expression pattern of the COX-1
isoenzyme.
Spatial coupling between COX-1, mPGES, hPGDS, and
PGE2/D2 biosynthesis at the wound site In order to con¢rm
a correlation between COX-1 and wound PGE2/D2 biosynthesis,
we analyzed COX and PGES/PGDS as well as PGE2/D2
concentrations in distinct compartments of wound tissue. Tissue
was taken from 5 d old wounds and divided into the ‘‘wound
margin’’ (which contained part of the nonwounded epidermis
and dermis, and more importantly the complete developing
wound margin epithelia) and the ‘‘inner wound’’ (which
contained the complete developing granulation tissue consisting
predominantly of macrophages, ¢broblasts, and endothelial cells)
compartments. Determination of COX-1 and COX-2 isoenzyme
expression revealed a marked di¡erence in the distribution of the
enzymes in the wound tissue, where COX-1 comprised 80% of
the COX expression at the wound margins and COX-2 80%
of the expression within the inner wound (granulation tissue)
(Fig 3a). Interestingly, although mPGES and hPGDS have been
shown to be temporally coinduced with COX-2 after injury
(Fig 1b,e), we observed that mPGES and hPGDS expression was
signi¢cantly colocalized with COX-1 at the wound margins,
suggesting a coupling of both synthases to COX-1 rather than
COX-2 (Fig 3b). Moreover, a functional coupling at the
enzyme activity level could be established using LC/MS/MS
analysis of PGE2/D2 production (Fig 3c). The wound margins
thus constitute sites with the highest PGE2/D2 biosynthetic
activity in the wound. It is notable that the high levels of
inducible COX-2 in granulation tissue of the inner
compartment of the wound were not accompanied by any
substantial change in PGE2/D2 concentrations (Fig 3a,c). Thus, a
decreased substrate availability in the presence of elevated COX-2
protein expression might also contribute to the observed low
levels of PGE2/D2 within the granulation tissue; however, in
vitro experiments with cell lines, i.e., the murine macrophage
(RAW264.7) and ¢broblast (NIH 3T3) cell line, representing
two predominant cell types of wound granulation tissue,
con¢rmed the absence of coupling between induced COX-2
and PGE2/D2 synthesis in skin repair in vivo.With the exception
of mPGES, which is coinduced with COX-2 in cytokine-
stimulated 3T3 ¢broblasts, cPGES, hPGDS, and lPGDS were
not coexpressed in vitrowith COX-2 (Fig 3d).
Pharmacologic inhibition of COX-1, but not COX-2
activity interrupts PGE2/D2 biosynthesis in skin wounds
and impairs tissue regeneration At this point of this study
we had to address the possibility that the observed COX-1
coupled PGE2/D2 production has no functional role in the
repair process and that it represents an epiphenomenon with no
pivotal involvement. Thus, we analyzed the ability of PGE2/D2
to drive the repair process, as it could still be reasonable to
Figure 2. PGE2/D2 concentrations during skin repair. Concentrations of PGE2/D2 (pg per mg wound protein) in nonwounded skin and at the wound
site were determined by LC/MS/MS (right panel). npo0.05 (ANOVA, Bonferroni t test) compared as indicated by brackets. Bars indicate the mean7SD of
wounds (n¼ 9) isolated from three independent animal experiments. Mass transitions for speci¢c identi¢cation of PGE2/D2 (left panel).
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recognize highly induced COX-2 as the key enzyme to produce
PGH2 substratum for additional prostanoid biosynthetic
pathways and production of important functional messengers in
tissue repair. Thus, we treated mice either with the selective
COX-1 inhibitor SC-560, the selective COX-2 inhibitor
celecoxib or the nonselective COX inhibitor diclofenac in order
Figure 3. Spatial distribution of COX and PGE2/D2 synthase expression. RNase protection assay demonstrating distribution in expression of COX
(a) and PGE2/D2 synthase (b) at the wound margin and inner region of wound (granulation tissue) on day 5 after injury.
nnpo0.01; npo0.05 (Student’s t
test) as compared with wound margin. Bars (mean7SD) indicate the data for the various wound compartments isolated in three independent animal
experiments. (c) PGE2/D2 concentrations (pg per mg wound protein) determined by LC/MS/MS at wound margin and inner region of wound (granulation
tissue) 5 d after wounding. nnpo0.01 (Student’s t test) as compared with wound margin. (d) Coexpression of COX and PGE2/D2 synthase in cultured
murine 3T3 ¢broblasts and RAW264.7 macrophages determined using the RNase protection assay.
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to di¡erentiate the COX-1- and COX-2-speci¢c function during
repair. Animals received oral doses of the agents approximately
equivalent to those used therapeutically in humans (2.5 mg per
kg per 12 h), and LC/MS/MS analysis showed good systemic
availability of the drugs (Fig 4a). The COX-2 selective inhi-
bitor celecoxib, however, produced no signi¢cant reduction in
PGE2/D2 levels in the wounds compared with mock-treated
control animals (Fig 4b, left panel). This observation was not
unexpected, as our previous data had shown that PGE2/D2
biosynthesis was functionally coupled to COX-1 (Figs 1^3). In
accord with this interpretation, the selective COX-1 inhibitor
SC-560 as well as the nonselective COX inhibitor diclofenac
signi¢cantly inhibited the PGE2/D2 production in the wound
(Fig 4b, left panel).
The question of a functional role for COX-1-directed
inhibition of wound PGE2/D2 production, however, still
remained unsolved. In order to clarify this central point, we
examined the wound healing process histologically in celecoxib-
treated animals (selective COX-2 inhibitor), SC-560-treated
animals (selective COX-1 inhibitor) as well as diclofenac-treated
animals (nonselective COX inhibitor). Celecoxib treatment of
mice produced no change to the morphologic architecture of
the wound, and wound tissue from both mock- and celecoxib-
treated animals showed well-developed hyperproliferative
wound margin epithelia (he, indicated by a yellow line) and
granulation tissues (g), associated with a massive in¢ltration of
macrophages (mf) (Fig 4c). Epithelial cell numbers (Fig 4b,
right panel) and cellular proliferation rates (as assessed using
the proliferation marker Ki67) at the wound site in these experi-
ments were similar (Fig 4c, left panels); however, the oral
administration of SC-560 or diclofenac initiated changes in
wound morphology (Fig 4b, right panel; Fig 4d).Wounds from
SC-560-treated mice were characterized by a reduction in the
epithelia at the wound margins (Fig 4b, right panel; Fig 4d, he,
indicated by a yellow line), but well-developed granulation
tissues and macrophage in£ux. Nevertheless, diclofenac
treatment led to atrophied epithelial sites (Fig 4b, right panel;
Fig 4d, he, indicated by a yellow line) and granulation tissues
(gn) associated with a reduced in£ux of macrophages. To
con¢rm these observations, we treated mice with higher doses
of diclofenac (7.5 mg per kg per 12 h), where the parenteral (i.p.)
administration of diclofenac caused an approximately 2.5-fold
increase in plasma levels as compared with oral treatment
(Fig 5a). As a result of this treatment, levels of constitutive
PGE2/D2 were signi¢cantly reduced and more so in wounded
skin than in nonwounded skin (Fig 5a), and more so following
i.p. treatment than after oral administration (Figs 4b and 5a). The
morphologic changes were also more pronounced (Fig 5b,c upper
panel).Wounds of i.p. diclofenac-treated mice were characterized
by strongly reduced wound margin epithelia (he), and a nearly
Figure 4. Pharmacologic inhibition of COX-1 activity interferes with skin repair (I). (a) Plasma concentrations for celecoxib, SC-560, and diclo-
fenac following oral treatment of mice. Bars indicate the mean7SD from individual animals (n¼ 6). (b) PGE2/D2 concentrations (pg per mg wound
protein) in 5 d wounds as determined by LC/MS/MS (left panel) and keratinocyte cell numbers in the hyperproliferative epithelia of 5 d wounds (right panel)
of mock- and inhibitor-treated mice. npo0.05; n.s. (not signi¢cant) (ANOVA, Bonferroni t test) compared as indicated by brackets. Bars indicate the
mean7SD from wounds (n¼ 9 for the LC/MS/MS analysis; n¼ 5 for keratinocyte cell number analysis) isolated from three independent animal experi-
ments. (c,d) Immunohistologic analysis of wound morphology in mock- and inhibitor-treated mice 5 d postwounding as indicated. Sections were analyzed
for markers of proliferation (Ki67, left panels) and macrophages (F4/80, right panels). The yellow line marks the epithelial/mesenchymal border. he, hyperpro-
liferative epithelium; g, granulation tissue; gn, atrophied granulation tissue; mf, macrophage.
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complete loss of developing granulation tissues (gn). Cellular
proliferation was markedly reduced in keratinocytes, and
completely absent beneath the epithelia re£ecting the loss of
granulation tissues (Fig 5b). It was also noted that reduction in
immune cell in£ux observed initially with moderate doses of
diclofenac (Fig 4d) was even greater. Neutrophils (GR-1) and
macrophages (F4/80) accumulated at the wound margins but
they almost failed completely to in¢ltrate the wound site
(Fig 5b). Moreover, we assessed expression levels of the marker
transcripts lipocalin (constitutively expressed in neutrophils) or
lysozyme M (constitutively expressed in macrophages) at the
wound site. E¡ects of diclofenac on relative amounts of immune
cells at the wound margins revealed an in£uence on neutrophil,
but not macrophage accumulation (Fig 5d). In accord with
published data (Kunkel et al, 1988), we observed the expression
of TNF-a to be dependent on the COX status of the wound
tissue (Fig 5d). As a next step, we intended to shed more light
on how COX activities might in£uence the observed tissue
responses. To this end, we focused on the regulation of the
angiogenic VEGF, which was clearly downregulated at the
mRNA level in wounds of diclofenac-treated animals; however,
decreased VEGF mRNA levels were translated into a signi¢cant,
but only moderate reduction in VEGF protein (Fig 5e).
Nevertheless, we could not observe any changes in the
constitutively expressed endothelial cell marker CD31 in the
presence of COX enzymatic inhibition (Fig 5e). Whereas
immunohistochemistry con¢rmed CD31 expression in wounds
of diclofenac-treated mice, we could not detect the formation
of vascular structures from endothelial (CD31-positive) cells
within the strongly reduced granulation tissues (gn) of these
animals (Fig 5b, insert).
In order to obtain unequivocal evidence that at least COX-1-
coupled PGE2 synthesis plays an important part in skin repair, we
assessed the potency of PGE2 to reverse diclofenac-mediated
changes in wound tissue. To achieve this, the wounds of
diclofenac-treated mice (7.5 mg per kg per 12 h, i.p.) were
treated topically with PGE2 (dinoprostone 8 mg per wound in
10 ml triacetine/SiO2/12 h) for 5 d. Triacetine/SiO2 alone was
used as a mock control. It was observed that PGE2 is an active
PG in the COX-1/PG pathway. The topical administration of
PGE2 markedly improved the diclofenac-mediated morphologic
alterations associated with the atrophied epithelia at the margin
of the wound (Fig 5c).
COX-1-de¢cient mice exhibit wound healing disorders
similar to those in mice with a diclofenac-impaired COX-1
coupled PGE2/D2 biosynthetic pathway To prove ¢nally the
functional importance of COX-1-coupled PGE2/D2 synthesis
in skin repair, we used homozygous COX-1-de¢cient mice as
a model system (Langenbach et al, 1995). In accord with
our observation above showing that the functional coupling
between COX-1 and PGES/PGDS leads to PGE2/D2 production
in nonwounded (Fig 2) as well as injured skin (Figs 3^5), we
observed a complete lack of PGE2/D2 synthesis in normal skin
of homozygous COX-1 knockout mice (Fig 6a, left panel). It is
notable, that in the knockout model system also, there was a near
Figure 5. Pharmacologic inhibition of COX-1 activity interferes with skin repair (II). (a) plasma concentrations of diclofenac following systemic
administration in mice (left panel). Bars indicate the mean7SD from individual animals (n¼ 6). PGE2/D2 concentrations (pg per mg wound protein) in
nonwounded back skin and 5 d wounds of PBS- and inhibitor-treated mice as determined by LC/MS/MS (right panel). nnpo0.01 (Student’s t test) as
compared with PBS-treated control animals. Bars indicate the mean7SD from wounds (n¼ 9) isolated from three independent animal experiments. (b)
immunohistologic analysis of wound morphology in diclofenac-treated (i.p.) mice 5 d after injury. Sections were analyzed for markers of proliferation
(Ki67), neutrophils (GR-1), macrophages (F4/80), and endothelial cells (CD31) as indicated. The highlighted area (middle panel) is shown in higher magni¢ca-
tion in the lower panel. (c) Immunohistologic analysis of 5 d wounds from diclofenac-administered (i.p.) mice (upper panel) after topical treatment with
dinoprostone (lower panels). Sections were analyzed for proliferation marker Ki67. f, fat tissue; g, granulation tissue; gn, atrophied granulation tissue; he,
hyperproliferative epithelium; pmn, polymorphonuclear neutrophils; mf, macrophages. (d) RNase protection assay showing expression of various markers
of skin repair in PBS- and diclofenac-treated animals. (e) expression of VEGF mRNA (RNase protection assay) and protein (enzyme-linked immuno-
sorbent assay), or CD31 protein (immunoblot) in skin repair of PBS- and diclofenac-treated mice as indicated.
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complete loss of PGE2/D2 synthesis at the margin compartment
of the wound (Fig 6a, right panel), i.e., in that region where
PGE2/D2 production predominates (Fig 3c). In addition, the low
levels of PGE2/D2 in the inner wound compartments did not
di¡er signi¢cantly from those in the wild-type (Fig 6a, right
panel). It can be concluded therefore that the overall changes in
PGE2/D2 production (Fig 6a, middle panel) must be due to
absence of the COX-1 isoform in transgenic animals, and this is
supported by the ¢nding of an unaltered expression of COX-2 in
homozygous COX-1-de¢cient animals (Fig 6c). Most important,
PGE2/D2 production in nonwounded as well as wounded skin
from SC-560-treated mice (selective inhibitor of COX-1) clearly
re£ected the PGE2/D2 synthesis observed in skin and wounds
of COX-1-de¢cient mice (Fig 6d). Consistent with our
Figure 6. PGE2/D2 biosynthesis as well as wound architecture is severely impaired in COX-1-de¢cient mice. (a) PGE2/D2 concentrations (pg per
mg wound protein) in nonwounded back skin (left panel), in total wound tissue isolated at day 5 after injury (middle panel), and in separated wound compart-
ments from 5 d wounds (right panel) of wild-type (COX-1þ/þ ), heterozygous (COX-1þ/^), and homozygous (COX-1^/^) mice as assessed by LC/MS/MS.
npo0.05 (ANOVA, Bonferroni t test) compared as indicated by brackets (left and middle panel). nnpo0.01; n.s., not signi¢cant (Student’s t test) compared as
indicated by brackets (right panel). Bars indicate the mean7SD fromwounds (n¼10) isolated from ¢ve independent animals. (b) Number of keratinocytes in
hyperproliferative epithelia of wild-type (COX-1þ/þ ) and homozygous (COX-1^/^) mice 5 d after injury. Keratinocyte proliferation was determined by
immunostaining of the proliferation marker Ki67. nnpo0.01 (Student’s t test) as compared with conditions indicated by brackets. Bars indicate the
mean7SD from ¢ve wounds (n¼ 5) isolated from ¢ve independent animals. (c) RNase protection assay showing the expression pattern of COX-2 in back
skin or 5 d wounds isolated fromwild-type (COX-1þ/þ ), heterozygous (COX-1þ/^), and homozygous (COX-1^/^) mice. (d) PGE2/D2 concentrations (pg
per mg wound protein) in nonwounded back skin (left panel) and 5 d wounds (right panel) of mock- and SC-560-treated BALB/c mice as assessed by
LC/MS/MS. nnpo0.01; n.s., not signi¢cant (Student’s t test) as compared with conditions indicated by brackets. Bars indicate the mean7SD from
wounds (n¼10) isolated from ¢ve independent animals. (e) Immunohistochemical analysis of wound morphology (day 5 postwounding) in wild-type
(COX-1þ/þ ) and homozygous (COX-1^/^) mice. The yellow line marks the epithelial/mesenchymal border. g, granulation tissue; he, hyperproliferative
epithelium.
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pharmacologic data, attenuated PGE2/D2 levels in wounds of
COX-1-de¢cient mice ¢nally resulted in reduced epithelia at the
margin of the wound (he, indicated by a yellow line) (Fig 6e).
Notably, we observed a marked and signi¢cant reduction in
keratinocyte proliferation rates within the smaller and £attened
epithelial tongues (Fig 6b,e), a phenomenon that was also observed
in the interference experiments with SC-560 or diclofenac and
could be reversed by dinoprostone (Figs 4d and 5b,c).
DISCUSSION
PG biosynthesis in mammalian cells occurs at three distinct
regulatory levels. AA is released from membrane glycerophos-
pholipids by phospholipase A2 isoenzymes and subsequently me-
tabolized by COX activities via PGH2 into bioactive PG by the
various PG synthases. It has been known for some time that im-
mediate and delayed PG synthesis are both associated with typical
in£ammatory responses and that they might be controlled by the
availability of AA substrate. Thus, COX-1-coupled PG biosynth-
esis is favored over COX-2 directed synthesis in the presence of
high AA concentrations, whereas COX-2 driven PG pathways
predominate at lower concentrations of AA (Murakami et al,
1999). Thus, it is reasonable to suggest that normal skin tissue
drives COX-1-coupled PG synthesis, as constitutively expressed
cytosolic PLA2 is present in skin keratinocytes (Fˇrstenberger
et al, 1997; Li-Stiles et al, 1998).The occurrence of PGE2/D2 in nor-
mal skin clearly supports a PG biosynthetic pathway coupled to a
constitutively active COX-1 enzyme, as there was little or no ex-
pression of the inducible COX-2 isoform.This interpretation also
explains the complete absence of PGE2/D2 in nonwounded skin
of COX-1-de¢cient mice. Accordingly, COX-1 protein has been
localized in individual basal and suprabasal keratinocytes of the
epidermis and in hair follicles (Scholz et al, 1995). Taken together,
these data suggest that the COX-1 isoenzyme contributes to
skin homeostasis. The possibility that COX-derived PG have a
functional role in normal skin is supported by the basal keratino-
cyte-targeted overexpression of COX-2 in the transgenic mouse
model. Transgenic animals are characterized by having elevated
levels of PGE2 and PGF2a in skin as well as a reduced hair follicle
density, sebaceous gland hyperplasia and a hyperplastic scale epi-
dermis resulting from a disturbance in keratinocyte di¡erentia-
tion (Neufang et al, 2001). Accordingly, increased levels of PGE2
have been associated with high proliferation rates in keratinocytes
(Pentland and Needleman, 1986), and it is now suggested that ker-
atinocyte proliferation is closely linked to the presence of a func-
tionally active COX-2 (Loftin and Eling, 1996). In line with these
in vitro data, COX-2, but not the COX-1 isoenzyme, is reported
to be increased in hyperplastic conditions of the skin such as pa-
pillomas and carcinomas in the mouse (Mˇller-Decker et al, 1995;
Pentland et al, 1999; Athar et al, 2001), and in keratoses and squa-
mous cell carcinomas in humans (Mˇller-Decker et al, 1999). A
very recent study, however, implicated both COX isoenzymes
in keratinocyte di¡erentiation, as early di¡erentiation stages were
primarily a¡ected in COX-1- and COX-2-de¢cient mice. The
absence of either isoform caused a premature terminal di¡erentia-
tion of initiated keratinocytes in models of induced tumor for-
mation (Tiano et al, 2002). Thus, it is reasonable to suggest a role
for COX-2 in the controlled delay in di¡erentiation observed for
the hyperproliferative epithelial sites at the margins of the
wound. Additionally, the capacity of COX-2 to produce anti-in-
£ammatory PG (Smith and Langenbach, 2001) might serve a reg-
ulatory role to control acute in£ammatory processes during
repair.
This study sheds more light on the aforementioned reports, as
we provide strong evidence for a tight functional coupling be-
tween COX-1, rather than COX-2, and tissue changes during
murine skin repair, and, in particular, with respect to keratino-
cyte behavior. First, wound tissue PGE2/D2 levels were lowest at
day 1 after wounding when COX-1 protein was almost nonde-
tectable. Interestingly, the rapid and marked induction in COX-
2, occurring in parallel, did not result in an increased amounts of
PGE2/D2. Secondly, at the margin of the wound, which includes
the highly proliferative wound keratinocytes, COX-1 expression
predominated over COX-2 expression, and this expression was
associated with mPGES and hPGDS isoforms, and the highest
concentrations of PGE2/D2 in the wound. Thirdly, although
plasma levels indicated good systemic availability, the COX-2 se-
lective inhibitor, celecoxib (Fitzgerald and Patrono, 2001), failed
to reduce wound PGE2/D2 levels signi¢cantly as assessed 5 d after
injury, a time point when repair is characterized by a maximal
induction of COX-2 and reappearance of COX-1. We favored
the use of celecoxib in vivo rather than a wound model in COX-
2-de¢cient mice, because these animals exhibit a markedly re-
duced viability that could interfere with the surgical wounding
procedure as well as interpretation of the events in repair pro-
cesses (Dinchuk et al, 1995). In contrast, diclofenac, which
potently inhibits both COX isoenzymes, was capable of reducing
PGE2/D2 formation. Our pharmacologic experiments demon-
strate clearly that COX-1 is the important initiating enzyme in
the PGE2/D2 biosynthetic pathway. Fourthly, COX-1 knockout
mice show an almost complete loss of PGE2/D2 production at
the margins of the wound. Finally, and most important, diclofe-
nac, but not the COX-2 selective inhibitor celecoxib, is capable of
interfering with formation of the normal wound architecture in a
concentration-dependent manner. In agreement with the inhibi-
tor data, COX-1 knockout mice also display an impaired wound
phenotype characterized by markedly reduced proliferation of
keratinocytes at the margins of the wound. It remains puzzling
that the COX-2-derived PGE2/PGD2 product did not e¡ectively
contribute to epithelial movements, although both COX isoen-
zymes were coexpressed at the same epithelial sites at the margins
of the wound. One might speculate that AA is speci¢cally chan-
neled from phospholipases to COX-1 and PG synthases through a
tightly linked subcellular localization. In accord, selective inhibi-
tion of COX-1 by SC-560 and COX-1-de¢cient mice revealed
that PGE2/PGD2 indeed was derived almost completely from
the COX-1-coupled biosynthetic pathway at the margins of the
wound. Thus, the lack of COX-2-derived PG to drive keratino-
cyte behavior might be explained on a quantitative, but not ne-
cessarily, on a qualitative basis.
The complexity of the PG biosynthetic machinery is high-
lighted by a series of recent ¢ndings suggesting a segregated
functional coupling of distinct PG biosynthetic enzymes to the
COX isoforms even when both COX enzymes are coexpressed
within the same cell, and when both immediate and delayed in-
£ammatory responses occur (Naraba et al, 1998). In agreement
with this hypothesis, cotransfection experiments with single cat-
alytic components of distinct PG synthetic pathways revealed
functional coordination involving COX-1 and cPGES (Tanioka
et al, 2000) or hPGDS (Ueno et al, 2001), and COX-2 and mPGES
(Murakami et al, 2000), thromboxane synthase, or prostacyclin
synthase (Ueno et al, 2001). During skin repair, we observed
a functional coupling between COX-1, mPGES, and hPGDS ex-
pression and activity. Moreover, PGE2/D2 biosynthesis at the
wound margins was almost completely dependent on COX-1 ac-
tivity. Obviously, the role of COX-1 postulated from in vitro ex-
periments does not necessarily re£ect the in vivo situation in the
setting of wound healing. Nevertheless, speci¢city of PGE2 or
PGD2 functions, respectively, is mediated via expression of di¡er-
ent PGE2 (EP) or PGD2 (DP) receptor subsets on di¡erent cell
lineages during repair.We observed an increased chemotactic re-
sponse of neutrophils (although cells failed to enter the central
wound as the granulation tissue was atrophied) in diclofenac-
treated mice. In line with this observation, PGE2 is known to in-
hibit neutrophil chemotaxis via the EP2 receptor (Armstrong,
1995). In addition, PGD2 is rapidly metabolized to 15-deoxy-
D12,14 -PGJ2, which represents a potent agonist of the nuclear re-
ceptor peroxisome proliferator-activated receptor-g (Khan, 1995).
As peroxisome proliferator-activated receptor-g is present at high
levels in activated macrophages, 15-deoxy-D12,14 -PGJ2 mediates a
decreased cytokine release from these cells (Jiang et al, 1998). In
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accord, we observed higher expression levels of TNF-a in
wounds of diclofenac-treated mice in the presence of unaltered
numbers of macrophages at the wound site.
Information has been published on the possible role of COX
enzymes in the healing of gastric ulcers. This information is of
clinical importance in regard to the severe gastrointestinal
side-e¡ects seen during treatment with NSAID (Soll et al, 1991);
however, and in clear contrast to skin repair, induction of gastric
ulcers is not associated with a change in COX-1mRNA and pro-
tein expression (Mizuno et al, 1997; Takahashi et al, 1998).
During repair in skin (this study) and in the stomach (Mizuno
et al, 1997; Takahashi et al, 1998), COX-2 expression at least ful¢lls
its ‘‘expected’’ role as the inducible component in the prostanoid
synthesizing machinery. Moreover, COX-2 protein was present
at the ulcer site expressed in granulocytes and macrophages, re-
sembling the situation in skin repair. There may, however, be
marked di¡erences between skin wounds and gastric ulcers in
the overall COX activities and subsequent PG production at the
wound site. For example, in ulcers the PGE2 levels appear to be
elevated (Mizuno et al, 1997;Takahashi et al, 1998), whereas COX-1
expression is constant indicating that the induction of COX-2 is
responsible for increased PG synthesis at the gastric wound site.
The observation that selective inhibition of COX-2 during gas-
tric repair severely impairs the healing process (Mizuno et al,
1997) underlines the importance of COX-2-derived PG. The be-
havior of COX-2 here, markedly contrasts with its role in cuta-
neous healing, where the enzyme is rapidly and highly induced
after wounding, and where wound PGE2/D2 biosynthesis de-
clines dramatically. Moreover, the inhibition of COX-2 does not
alter the tissue repair processes when examined histologically. It
has long been known that macrophage-derived TNF-a expres-
sion is under a negative regulatory loop of PGE2 (Kunkel et al,
1988). In agreement with this, we found an elevated expression
of TNF-a in wounds isolated from diclofenac-treated mice in
the presence of equal numbers of macrophages. Additionally, we
found a reduced VEGF expression after COX inhibition. At-
tenuation of VEGF expression in inhibitor-treated mice, how-
ever, might be the consequence of reduced epithelia at the
margin of the wound, which are well known as the main produ-
cers of this important endothelial mitogen in normal skin
repair. Nevertheless, it was not unexpected that the atrophied
granulation tissues in wounds of inhibitor-treated mice did not
form new blood vessel structures. A most recent study further
strengthens a regulatory role of PG in skin repair, as incisional
wounds from COX-1- and COX-2-de¢cient mice were charac-
terized by a reduced wound breaking strength as assessed at day
12 postwounding (Laulederkind et al, 2002). Evidently, COX-1-
coupled PGE2 represents an important messenger molecule in the
PG axis. Topical application of PGE2 (dinoprostone) almost com-
pletely reverses the tissue growth defects occurring on pharmaco-
logic inhibition of COX-1-mediated PG production. Our
data suggest, that despite a marked induction of COX-2 follow-
ing injury, COX-1 is the central player in normal skin repair,
evidencing that a simpli¢ed estimation of COX-1 as the constitu-
tive and the inducible COX-2 as the ‘‘alert’’ COX isoenzyme
might not be applicable for in£ammatory conditions during skin
repair.
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